Abstract
Background Major depressive disorder (MDD) is accompanied by activated neuro-immune pathways, increased physiosomatic and chronic fatigue-fibromyalgia (FF) symptoms. The most severe MDD phenotype, namely major dysmood disorder (MDMD), is associated with adverse childhood experiences (ACEs) and negative life events (NLEs) which induce cytokines/chemokines/growth factors.
Aims To delineate the impact of ACE+NLEs on physiosomatic and FF symptoms in first episode (FE)-MDMD, and examine whether these effects are mediated by immune profiles.
Methods ACEs, NLEs, physiosomatic and FF symptoms, and 48 cytokines/chemokines/growth factors were measured in 64 FE-MDMD patients and 32 normal controls.
Results Physiosomatic, FF and gastro-intestinal symptoms belong to the same factor as depression, anxiety, melancholia, and insomnia. The first factor extracted from these seven domains is labeled the physio-affective phenome of depression. A part (59.0%) of the variance in physiosomatic symptoms is explained by the independent effects of interleukin (IL)-16 and IL-8 (positively), CCL3 and IL-1 receptor antagonist (inversely correlated). A part (46.5%) of the variance in physiosomatic (59.0%) symptoms is explained by the independent effects of interleukin (IL)-16, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (positively) and combined activities of negative immunoregulatory cytokines (inversely associated). Partial Least Squares analysis shows that ACE+NLEs exert a substantial influence on the physio-affective phenome which are partly mediated by an immune network composed of IL-16, CCL27, TRAIL, macrophage-colony stimulating factor, and stem cell growth factor.
Conclusions The physiosomatic and FF symptoms of FE-MDMD are partly caused by immune-associated neurotoxicity due to T helper (Th)-1 polarization, Th-1, and M1 macrophage activation and relative lowered compensatory immunoregulatory protection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The C2F program at Chulalongkorn University in Thailand, grant number 64.310/436/2565 to AFA, the Thailand Science Research, and Innovation Fund at Chulalongkorn University (HEA663000016), and a Sompoch Endowment Fund (Faculty of Medicine) MDCU (RA66/016) to MM all provided funding for the project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The College of Medical Technology at The Islamic University of Najaf, Iraq (18/2021) approved the research project. Our IRB follows the International Guideline for Human Research Safety, as well as the World Medical Association Declaration of Helsinki, The Belmont Report, the CIOMS Guideline, and the International Conference on Harmonization of Good Clinical Practice, and our study was conducted in accordance with all applicable Iraqi and international ethics and privacy laws. (ICH-GCP). Before participating in the study, all participants, or, if applicable, their parents or legal custodians, provided informed consent in writing. Document No. 18/2021 indicates that the Ethics Committee of the College of Medical Technology at the Islamic University of Najaf in Iraq has approved this investigation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Availability of data
The corresponding author (MM) will make the SPSS file used in the current study available upon receipt of an appropriate request and once the author has fully exploited the data.
